Comparison of thrombogenicity in different types of drug-eluting stents during transition from DAPT to SAPT.
coronary artery disease
drug‐eluting stent
dual antiplatelet therapy
rebound effect
single antiplatelet therapy
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
20 May 2024
20 May 2024
Historique:
revised:
13
04
2024
received:
05
10
2023
accepted:
07
05
2024
medline:
21
5
2024
pubmed:
21
5
2024
entrez:
21
5
2024
Statut:
aheadofprint
Résumé
During the transition from dual antiplatelet therapy (DAPT) to single antiplatelet therapy (SAPT), previous studies have raised concerns about a rebound effect. We compared platelet and inflammatory cell adhesion on different types of stents in the setting of clopidogrel presence and withdrawal. In Experiment 1, three pigs were administered with DAPT, that is, clopidogrel and acetylsalicylic acid (ASA), for 7 days. Each animal underwent an extracorporeal carotid arteriovenous shunt model implanted with fluoropolymer-coated everolimus-eluting stent (FP-EES), biodegradable-polymer sirolimus-eluting stent (BP-SES), and biodegradable-polymer everolimus-eluting stents (BP-EES). In Experiment 2, two pigs were administered DAPT, clopidogrel was then withdrawn at day 7, and SAPT with ASA was continued for next 21 days. Then flow-loop experiments with the drawn blood from each time point were performed for FP-EES, BioLinx-polymer zotarolimus-eluting stents (BL-ZES), and BP-EES. The rebound effect was defined as the statistical increase of inflammation and platelet adhesion assessed with immunohistochemistry on the stent-strut level basis from baseline to day-14 or 28. Both experiments showed platelet adhesion value was highest in BP-EES, while the least in FP-EES during DAPT therapy. There was no increase in platelet or inflammatory cell adhesion above baseline values (i.e., no therapy) due to the cessation of clopidogrel on the stent-strut level. Monocyte adhesion was the least for FP-EES with the same trend observed for neutrophil adhesion. No evidence of rebound effect was seen after the transition from DAPT to SAPT. FP-EES demonstrated the most favorable antithrombotic and anti-inflammatory profile regardless of the different experimental designs.
Sections du résumé
BACKGROUND
BACKGROUND
During the transition from dual antiplatelet therapy (DAPT) to single antiplatelet therapy (SAPT), previous studies have raised concerns about a rebound effect. We compared platelet and inflammatory cell adhesion on different types of stents in the setting of clopidogrel presence and withdrawal.
METHODS
METHODS
In Experiment 1, three pigs were administered with DAPT, that is, clopidogrel and acetylsalicylic acid (ASA), for 7 days. Each animal underwent an extracorporeal carotid arteriovenous shunt model implanted with fluoropolymer-coated everolimus-eluting stent (FP-EES), biodegradable-polymer sirolimus-eluting stent (BP-SES), and biodegradable-polymer everolimus-eluting stents (BP-EES). In Experiment 2, two pigs were administered DAPT, clopidogrel was then withdrawn at day 7, and SAPT with ASA was continued for next 21 days. Then flow-loop experiments with the drawn blood from each time point were performed for FP-EES, BioLinx-polymer zotarolimus-eluting stents (BL-ZES), and BP-EES. The rebound effect was defined as the statistical increase of inflammation and platelet adhesion assessed with immunohistochemistry on the stent-strut level basis from baseline to day-14 or 28.
RESULTS
RESULTS
Both experiments showed platelet adhesion value was highest in BP-EES, while the least in FP-EES during DAPT therapy. There was no increase in platelet or inflammatory cell adhesion above baseline values (i.e., no therapy) due to the cessation of clopidogrel on the stent-strut level. Monocyte adhesion was the least for FP-EES with the same trend observed for neutrophil adhesion.
CONCLUSIONS
CONCLUSIONS
No evidence of rebound effect was seen after the transition from DAPT to SAPT. FP-EES demonstrated the most favorable antithrombotic and anti-inflammatory profile regardless of the different experimental designs.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : CVPath Institute
Organisme : Abbott Vascular
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Généreux P, Giustino G, Witzenbichler B, et al. Incidence, predictors, and impact of post‐discharge bleeding after percutaneous coronary intervention. J Am Coll Cardiol. 2015;66(9):1036‐1045.
Watanabe H, Domei T, Morimoto T, et al. Effect of 1‐month dual antiplatelet therapy followed by clopidogrel vs 12‐month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT‐2 randomized clinical trial. JAMA. 2019;321(24):2414‐2427.
Vranckx P, Valgimigli M, Jüni P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug‐eluting stent: a multicentre, open‐label, randomised superiority trial. Lancet. 2018;392(10151):940‐949.
Hahn JY, Song YB, Oh JH, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART‐CHOICE randomized clinical trial. JAMA. 2019;321(24):2428‐2437.
Baber U, Dangas G, Cohen DJ, et al. Ticagrelor with aspirin or alone in high‐risk patients after coronary intervention: rationale and design of the TWILIGHT study. Am Heart J. 2016;182:125‐134.
Kim BK, Hong SJ, Cho YH, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA. 2020;323(23):2407‐2416.
Ong ATL, McFadden EP, Regar E, de Jaegere PPT, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug‐eluting stents. J Am Coll Cardiol. 2005;45(12):2088‐2092.
Weimar C, Cotton D, Sha N, et al. Discontinuation of antiplatelet study medication and risk of recurrent stroke and cardiovascular events: results from the PRoFESS study. Cerebrovasc Dis. 2013;35(6):538‐543.
Pfisterer M, Brunner‐La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation May limit the benefit of drug‐eluting stents. J Am Coll Cardiol. 2006;48(12):2584‐2591.
Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug‐eluting stents. N Engl J Med. 2014;371(23):2155‐2166.
Stefanescu Schmidt AC, Kereiakes DJ, Cutlip DE, et al. Myocardial infarction risk after discontinuation of thienopyridine therapy in the randomized DAPT study (Dual Antiplatelet Therapy). Circulation. 2017;135(18):1720‐1732.
Ho PM. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA. 2008;299(5):532‐539.
Ford I. Coming safely to a stop: a review of platelet activity after cessation of antiplatelet drugs. Ther Adv Drug Saf. 2015;6(4):141‐150.
Sambu N, Warner T, Curzen N. Clopidogrel withdrawal: is there a “rebound” phenomenon? Thromb Haemost. 2011;105(2):211‐220.
Ford I, Scott NW, Herd V, Mitchell LR, Williams DJP, Brittenden J. A randomized controlled trial of platelet activity before and after cessation of clopidogrel therapy in patients with stable cardiovascular disease. J Am Coll Cardiol. 2014;63(3):233‐239.
Frelinger 3rd AL, Barnard MR, Fox ML, Michelson AD. The platelet activity after clopidogrel termination (PACT) study. Circ Cardiovasc Interventions. 2010;3(5):442‐449.
Otsuka F, Cheng Q, Yahagi K, et al. Acute thrombogenicity of a durable polymer everolimus‐eluting stent relative to contemporary drug‐eluting stents with biodegradable polymer coatings assessed ex vivo in a swine shunt model. JACC: Cardiovasc Interventions. 2015;8(9):1248‐1260.
Jinnouchi H, Kutyna M, Torii S, et al. Comparison of acute thrombogenicity and albumin adsorption in three different durable polymer coronary drug‐eluting stents. EuroIntervention. 2021;17(3):248‐256.
Torii S, Cheng Q, Mori H, et al. Acute thrombogenicity of fluoropolymer‐coated versus biodegradable and polymer‐free stents. EuroIntervention. 2019;14(16):1685‐1693.
Sato Y, Jinnouchi H, Kolodgie FD, et al. Acute thrombogenicity of fluoropolymer coated stents versus competitive drug‐eluting stents under single antiplatelet therapy. Int J Cardiol. 2021;338:42‐49.
Jinnouchi H, Mori H, Cheng Q, et al. Thromboresistance and functional healing in the COBRA PzF stent versus competitor DES: implications for dual antiplatelet therapy. EuroIntervention. 2019;15(4):e342‐e353.
Savcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost. 1999;25 Suppl 2(suppl 2):15‐19.
Cornelissen A, Kutyna M, Cheng Q, et al. Effects of simulated COVID‐19 cytokine storm on stent thrombogenicity. Cardiovasc Revasc Med. 2022;35:129‐138.
Jinnouchi H, Sato Y, Cheng Q, et al. Thromboresistance and endothelial healing in polymer‐coated versus polymer‐free drug‐eluting stents: implications for short‐term dual anti‐platelet therapy. Int J Cardiol. 2021;327:52‐57.
Piccolo R, Feres F, Abizaid A, et al. Risk of early adverse events after clopidogrel discontinuation in patients undergoing short‐term dual antiplatelet therapy. JACC: Cardiovasc Interventions. 2017;10(16):1621‐1630.
Sibbing D, Stegherr J, Braun S, et al. A double‐blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment. J Am Coll Cardiol. 2010;55(6):558‐565.
Yedidya I, Netzer A, Vaduganathan M, Solodky A, Kornowski R, Lev EI. Clopidogrel tapering as a strategy to attenuate platelet rebound phenomenon in patients with bare‐metal stents. J Thromb Thrombolysis. 2012;33(1):16‐21.
Watanabe H, Morimoto T, Natsuaki M, et al. Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT‐2 ACS randomized clinical trial. JAMA Cardiol. 2022;7(4):407‐417.
Lee YJ, Cho JY, Yun KH, et al. Impact of one‐month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised one‐month DAPT trial. EuroIntervention. 2022;18(6):471‐481.
Szott LM, Irvin CA, Trollsas M, Hossainy S, Ratner BD. Blood compatibility assessment of polymers used in drug eluting stent coatings. Biointerphases. 2016;11(2):029806.
Mori H, Otsuka F, Gupta A, et al. Revisiting the role of durable polymers in cardiovascular devices. Expert Rev Cardiovasc Ther. 2017;15(11):835‐846.
Mehran R, Cao D, Angiolillo DJ, et al. 3‐ or 1‐Month DAPT in patients at high bleeding risk undergoing Everolimus‐eluting stent implantation. JACC: Cardiovascular Interventions. 2021;14(17):1870‐1883.
Virmani R. Drug eluting stents: are human and animal studies comparable? Heart. 2003;89(2):133‐138.